These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16101222)

  • 21. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
    Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
    Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aurora kinase A in Barrett's carcinogenesis.
    Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
    Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
    Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Barrett's oesophagus: the new endoscopic modalities have a future.
    Deviere J
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
    Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH
    Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular findings in Barrett's epithelium.
    Tannapfel A
    Dig Dis; 2004; 22(2):126-33. PubMed ID: 15383753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and Barrett's carcinogenesis.
    Poehlmann A; Kuester D; Malfertheiner P; Guenther T; Roessner A
    Pathol Res Pract; 2012 May; 208(5):269-80. PubMed ID: 22541897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
    Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
    Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hallmarks of cancer progression in Barrett's oesophagus.
    Morales CP; Souza RF; Spechler SJ
    Lancet; 2002 Nov; 360(9345):1587-9. PubMed ID: 12443613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
    Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
    González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
    J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA; Remotti H; Baergen RN; Altorki NK
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barrett's oesophagus--a pathologist's view.
    Fléjou JF; Svrcek M
    Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.